发布求助
文献互助 智能选刊 最新文献

Hepatic Oncology最新文献

筛选
英文 中文
Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada. 利用加拿大不列颠哥伦比亚省的真实数据了解肝细胞癌患者的治疗历程。
IF 5
Hepatic Oncology Pub Date : 2024-03-14 eCollection Date: 2023-12-01 DOI: 10.2217/hep-2023-0004
Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies
{"title":"Treatment journey of patients with hepatocellular carcinoma using real-world data in British Columbia, Canada.","authors":"Soo Jin Seung, Hasnain Saherawala, Brandon Zagorski, Carman Tong, Howard Lim, Peter Kim, Vladimir Marquez, Sharlene Gill, David Liu, Janine M Davies","doi":"10.2217/hep-2023-0004","DOIUrl":"10.2217/hep-2023-0004","url":null,"abstract":"<p><strong>Aim: </strong>This study examined treatment patterns, survival outcomes and healthcare costs related to hepatocellular carcinoma (HCC) in British Columbia.</p><p><strong>Methods: </strong>The study utilized data from two physician databases (HCC and MOTION) and the provincial British Columbia transplant database.</p><p><strong>Results: </strong>The analysis revealed diverse treatment approaches and identified the varying treatment journeys of patients. Liver transplant and systemic therapies demonstrated improved survival rates. However, there was a scarcity of Canadian-specific cost data.</p><p><strong>Conclusion: </strong>The research emphasizes the complexities of managing HCC and underscores the need for personalized treatment strategies to enhance patient outcomes. These findings contribute valuable insights into HCC management and provide a foundation for future studies and interventions aimed at optimizing care and resource allocation.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"10 4","pages":"HEP50"},"PeriodicalIF":5.0,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The predictive value of liver tests for the presence of liver metastases. 肝脏检查对肝转移的预测价值。
IF 5
Hepatic Oncology Pub Date : 2023-10-12 eCollection Date: 2023-09-01 DOI: 10.2217/hep-2023-0003
Alexandra V Kimchy, Harjit Singh, Esha Parikh, Jessica Rosenberg, Kavya Sanghavi, James H Lewis
{"title":"The predictive value of liver tests for the presence of liver metastases.","authors":"Alexandra V Kimchy,&nbsp;Harjit Singh,&nbsp;Esha Parikh,&nbsp;Jessica Rosenberg,&nbsp;Kavya Sanghavi,&nbsp;James H Lewis","doi":"10.2217/hep-2023-0003","DOIUrl":"10.2217/hep-2023-0003","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the predictive value of biochemical liver tests in patients with malignant melanoma, breast, colorectal or lung cancers at the time of diagnosis of liver metastases.</p><p><strong>Methods: </strong>A retrospective review of patients with the above-mentioned solid tumors at MedStar Georgetown University Hospital from 2016-2020.</p><p><strong>Results: </strong>The highest optimal cutoff according to sensitivity and specificity for the presence of liver metastases was for AST ≥1.5 × ULN for melanoma, lung, and breast cancers and ≥2 × ULN for colorectal cancer, ALT ≥1.25 × ULN for melanoma, breast and colorectal cancers and ≥1.5 × ULN for lung cancer, and ALP ≥1.5 × ULN for melanoma, breast and colorectal cancers.</p><p><strong>Conclusion: </strong>Using thresholds of liver enzymes above the ULN may improve the diagnostic accuracy for the presence of liver metastases.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"10 3","pages":"HEP48"},"PeriodicalIF":5.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54231527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study. 肝动脉灌注化疗加或不加乐伐替尼治疗不可切除胆管癌：一项单中心回顾性研究。
IF 5
Hepatic Oncology Pub Date : 2023-09-29 eCollection Date: 2023-06-01 DOI: 10.2217/hep-2023-0006
Yajing Wang, Zhanqi Wei, Zheng Zhang, Jingyi Xu, Yaqin Wang, Qian Chen, Yuewei Zhang
{"title":"Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma: a single-center retrospective study.","authors":"Yajing Wang,&nbsp;Zhanqi Wei,&nbsp;Zheng Zhang,&nbsp;Jingyi Xu,&nbsp;Yaqin Wang,&nbsp;Qian Chen,&nbsp;Yuewei Zhang","doi":"10.2217/hep-2023-0006","DOIUrl":"10.2217/hep-2023-0006","url":null,"abstract":"<p><strong>Aim: </strong>The purpose of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil and leucovorin (FOLFOX) plus lenvatinib and FOLFOX-HAIC alone in patients with unresectable cholangiocarcinoma.</p><p><strong>Patients & methods: </strong>Retrospective analysis of patients receiving FOLFOX-HAIC with or without lenvatinib.</p><p><strong>Results: </strong>Forty-one patients were included, with 22 patients receiving HAIC alone and 19 patients receiving HAIC plus lenvatinib. Combination treatment significantly prolonged overall survival and progression-free survival compared with HAIC alone. Grade 1-2 adverse events were more frequent in the combination group but manageable. No severe AEs or treatment-related deaths were reported.</p><p><strong>Conclusion: </strong>FOLFOX-HAIC plus lenvatinib has the potential to be a treatment option for unresectable cholangiocarcinoma.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"10 2","pages":"HEP49"},"PeriodicalIF":5.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/57/hep-10-49.PMC10577516.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting. 按Child-Pugh分级对社区肿瘤科晚期肝细胞癌患者的临床疗效。
IF 1.2
Hepatic Oncology Pub Date : 2023-08-09 eCollection Date: 2023-03-01 DOI: 10.2217/hep-2023-0002
Abdalla Aly, Nicole Fulcher, Brian Seal, Trang Pham, Yunfei Wang, Scott Paulson, Aiwu R He
{"title":"Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology setting.","authors":"Abdalla Aly, Nicole Fulcher, Brian Seal, Trang Pham, Yunfei Wang, Scott Paulson, Aiwu R He","doi":"10.2217/hep-2023-0002","DOIUrl":"10.2217/hep-2023-0002","url":null,"abstract":"<p><strong>Aim: </strong>Many pivotal trials in advanced hepatocellular carcinoma (HCC) require participants to have Child-Pugh A disease. However, many patients in real-world practice are Child-Pugh B or C. This study examined treatment patterns and clinical outcomes in patients with advanced HCC treated with first-line systemic therapy.</p><p><strong>Materials & methods: </strong>In this retrospective study, patients with HCC treated with first-line systemic therapy (2010-2017) were identified from US Oncology Network records. Outcomes included overall survival and progression-free survival, by Child-Pugh Class and prior liver-directed therapy.</p><p><strong>Results: </strong>Of 352 patients, 78.7% were Child-Pugh A or B, 96.6% received first-line sorafenib, and 33.8% received first-line-prior liver-directed therapy. Survival outcomes were similar for Child-Pugh A or B, and longer after first-line prior liver-directed therapy.</p><p><strong>Conclusion: </strong>First-line systemic therapy is beneficial in patients with Child-Pugh A or B, and after first-line prior liver-directed therapy. These findings may help position systemic therapy in the community setting.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"10 1","pages":"HEP47"},"PeriodicalIF":1.2,"publicationDate":"2023-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/26/7c/hep-10-47.PMC10413176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10352609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uncooled TATO microwave system for liver ablation. 用于肝脏消融的非冷却式TATO微波系统。
IF 5
Hepatic Oncology Pub Date : 2022-12-01 DOI: 10.2217/hep-2022-0002
Eduardo Crespo, Antonio Hermosín, Álvaro Villalba, Eduardo Daguer, José Flores, Javier Periañez, Mario Martínez-Galdámez, Ernesto Santos
{"title":"Uncooled TATO microwave system for liver ablation.","authors":"Eduardo Crespo,&nbsp;Antonio Hermosín,&nbsp;Álvaro Villalba,&nbsp;Eduardo Daguer,&nbsp;José Flores,&nbsp;Javier Periañez,&nbsp;Mario Martínez-Galdámez,&nbsp;Ernesto Santos","doi":"10.2217/hep-2022-0002","DOIUrl":"https://doi.org/10.2217/hep-2022-0002","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the safety and efficacy of uncooled TATO microwave ablation (MWA) for primary and metastatic liver cancer.</p><p><strong>Materials & methods: </strong>This was a retrospective study on percutaneous liver ablations performed with TATO MWA. Twenty-five ablations were performed; 11 (44%) were performed for hepatocellular carcinoma, 14 (56%) for colorectal carcinoma, gastric and pancreatic metastases.</p><p><strong>Results: </strong>Adverse events were reported only in one (4%) ablation: an abscess that was observed in the ablated area and was resolved with a percutaneous drainage and antibiotic therapy. Local tumor control rate was 92% at the 3-month follow-up.</p><p><strong>Conclusion: </strong>TATO MWA was safe and effective with high reproducibility in treating primary and secondary liver cancer with satisfactory technical and clinical outcomes.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 4","pages":"HEP46"},"PeriodicalIF":5.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/87/f5/hep-09-46.PMC10064260.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9753795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of hepatocellular carcinoma from diagnosis in routine clinical practice. 从临床常规诊断看肝癌的处理。
IF 5
Hepatic Oncology Pub Date : 2022-12-01 DOI: 10.2217/hep-2021-0011
Tasneem Lokhandwala, Abdalla Aly, Eileen Farrelly, Joanne P Willey, Lois E Lamerato, Marcus Healey, Anna D Coutinho, Brian S Seal
{"title":"Management of hepatocellular carcinoma from diagnosis in routine clinical practice.","authors":"Tasneem Lokhandwala,&nbsp;Abdalla Aly,&nbsp;Eileen Farrelly,&nbsp;Joanne P Willey,&nbsp;Lois E Lamerato,&nbsp;Marcus Healey,&nbsp;Anna D Coutinho,&nbsp;Brian S Seal","doi":"10.2217/hep-2021-0011","DOIUrl":"https://doi.org/10.2217/hep-2021-0011","url":null,"abstract":"<p><strong>Aim: </strong>To assess real-world management of patients diagnosed with hepatocellular carcinoma (HCC) within an integrated delivery network.</p><p><strong>Materials & methods: </strong>A retrospective cohort analysis of adults newly diagnosed with HCC from January 2014 to March 2019. Overall survival and treatment journey were assessed over the entire available follow-up period per patient.</p><p><strong>Results: </strong>Of the 462 patients, 85% had ≥1 treatment. The 24-month overall survival rate (95% CI) from first treatment was 77% (72-82%). Majority of Child-Pugh class A (71%) and B (60%) patients received locoregional therapy first. Half (53.6%) of the patients with liver transplantation first were Child-Pugh class C patients. Sorafenib was the predominant systemic therapy.</p><p><strong>Conclusion: </strong>This integrated delivery network data analysis offers a comprehensive insight into the real-world management of HCC.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 4","pages":"HEP45"},"PeriodicalIF":5.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/06/hep-09-45.PMC10064261.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9236012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient. 病理完全反应与免疫治疗和近距离治疗15转移性肝病变在一个病人。
IF 5
Hepatic Oncology Pub Date : 2022-09-27 eCollection Date: 2022-09-01 DOI: 10.2217/hep-2021-0014
Gokula Kumar Appalanaido, Muhamad Zabidi Ahmad, Syadwa Abdul Shukor, Alex Khoo Cheen Hoe, Manisekar K Subramaniam, Ang Soo Fan, Mohd Zahri Abdul Aziz
{"title":"Pathological complete response with immunotherapy and brachytherapy to 15 metastatic liver lesions in a single patient.","authors":"Gokula Kumar Appalanaido,&nbsp;Muhamad Zabidi Ahmad,&nbsp;Syadwa Abdul Shukor,&nbsp;Alex Khoo Cheen Hoe,&nbsp;Manisekar K Subramaniam,&nbsp;Ang Soo Fan,&nbsp;Mohd Zahri Abdul Aziz","doi":"10.2217/hep-2021-0014","DOIUrl":"https://doi.org/10.2217/hep-2021-0014","url":null,"abstract":"<p><strong>Materials & methods: </strong>High dose rate interstitial brachytherapy (HDR-IBT) treatment plan for 15 metastatic liver lesions in a patient with pancreatic cancer was retrieved and analyzed for liver dose parameters and diaphragm dose. Serial <sup>18</sup>F-FDG PET-CT scans were reviewed for disease response assessment and left liver lobe volume. Serial laboratory records were analyzed for liver parameters.</p><p><strong>Results: </strong>Left liver lobe volume increased from 241 cm<sup>3</sup> pre-HDR-IBT to estimated 600 cm<sup>3</sup> after seven sessions of HDR-IBT. Metabolic complete response (CR) and subsequently pathological CR was confirmed in the right hepatotectomy specimen for all the 15 PET-CT avid lesions treated with HDR-IBT. Maximum diaphragm dose in a single fraction was 82 Gy. The liver parameters were stable and patient did not develop radiation induced liver disease.</p><p><strong>Discussion: </strong>This is the largest reported series of HDR-IBT to liver lesions in a single patient. This first ever reported combined treatment of immunotherapy (IT) and HDR-IBT had likely rendered this patient disease free both at local the liver and systemically. Metabolic CR by PET-CT can be seen as early as 46 days after HDR-IBT. Diaphragm can tolerate very high doses of radiation and repeated treatment.</p><p><strong>Conclusion: </strong>In this patient HDR-IBT for multiple liver lesions with IT is well tolerated. PET-CT can be used for response assessment of HDR-IBT liver. Synergistic effect of IT with HDR-IBT and it's role as bridging for liver resection has clinical potential and should be further studied in prospective trials.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 3","pages":"HEP44"},"PeriodicalIF":5.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/73/hep-09-44.PMC9517960.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40383805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma. β受体阻滞剂对不可切除肝细胞癌患者生存结局的影响。
IF 5
Hepatic Oncology Pub Date : 2022-04-01 DOI: 10.2217/hep-2021-0010
Ellery Altshuler, Mahmoud Aryan, Govind Kallumkal, Hanzhi Gao, Jake Wilson, Ahmed Ouni, Edward De Leo, Wissam Hanayneh, Kelsey Pan
{"title":"Impact of β-blockers on survival outcomes in patients with unresectable hepatocellular carcinoma.","authors":"Ellery Altshuler,&nbsp;Mahmoud Aryan,&nbsp;Govind Kallumkal,&nbsp;Hanzhi Gao,&nbsp;Jake Wilson,&nbsp;Ahmed Ouni,&nbsp;Edward De Leo,&nbsp;Wissam Hanayneh,&nbsp;Kelsey Pan","doi":"10.2217/hep-2021-0010","DOIUrl":"https://doi.org/10.2217/hep-2021-0010","url":null,"abstract":"Background: β-blockers (BBs) have shown promise in improving overall survival (OS) in patients with breast, ovarian, pancreatic and lung cancer. However, few studies have evaluated the impact of BBs on unresectable hepatocellular carcinoma (HCC). Methods: The authors compared clinical data and outcomes between unresectable HCC patients based on whether they were prescribed BBs. Results: There was significantly decreased disease progression in the BB group compared with the non-BB group (22.8 vs 28.0%; p < 0.05). No difference was seen in OS or progression-free survival between groups. Those specifically on selective BBs had improved OS (hazard ratio: 0.75; 95% CI: 0.61–0.94; p = 0.01) and progression-free survival (hazard ratio: 0.66; 95% CI: 0.45–0.96; p = 0.03) compared with non-BB patients. Conclusion: Although the authors' study did not demonstrate that BBs improve OS in HCC, it did show decreased disease progression among patients with HCC who were taking BBs compared with those who were not.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"9 2","pages":"HEP43"},"PeriodicalIF":5.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0f/75/hep-09-43.PMC9136628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10601607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Portal vein embolization: rationale, techniques, outcomes and novel strategies. 门静脉栓塞:原理、技术、结果和新策略。
IF 5
Hepatic Oncology Pub Date : 2021-09-21 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2021-0006
Jirapa Chansangrat, Nattawut Keeratibharat
{"title":"Portal vein embolization: rationale, techniques, outcomes and novel strategies.","authors":"Jirapa Chansangrat,&nbsp;Nattawut Keeratibharat","doi":"10.2217/hep-2021-0006","DOIUrl":"https://doi.org/10.2217/hep-2021-0006","url":null,"abstract":"<p><p>The incidence of liver cancer has grown in the past decade, with 905,677 new cases and 830,180 deaths in 2020. According to the highest annual fatality ratio, liver cancer is the third-leading cause of cancer-related deaths worldwide. Surgical resection is the mainstay treatment for long-term survival. However, only 25% of patients are surgical candidates. Recent surgical concepts, techniques and multidisciplinary management were developed, including interventional radiology procedures that improve the management algorithm, expand the indications and limit dropouts from curative treatment. This review summarizes up-to-date information on interventional radiology in the management of liver tumors.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 4","pages":"HEP42"},"PeriodicalIF":5.0,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8a/c1/hep-08-42.PMC8577518.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Imaging of chemotherapy-induced liver toxicity: an illustrated overview. 化疗引起的肝毒性的影像学:图解概述。
IF 5
Hepatic Oncology Pub Date : 2021-09-15 eCollection Date: 2021-12-01 DOI: 10.2217/hep-2020-0026
Giovanni Brondani Torri, Matheus Dorigatti Soldatelli, Gustavo Felipe Luersen, Caroline Lorenzoni Almeida Ghezzi
{"title":"Imaging of chemotherapy-induced liver toxicity: an illustrated overview.","authors":"Giovanni Brondani Torri,&nbsp;Matheus Dorigatti Soldatelli,&nbsp;Gustavo Felipe Luersen,&nbsp;Caroline Lorenzoni Almeida Ghezzi","doi":"10.2217/hep-2020-0026","DOIUrl":"https://doi.org/10.2217/hep-2020-0026","url":null,"abstract":"<p><p>Chemotherapy is a potential cause of focal and diffuse hepatobiliary lesions. Many of these lesions may be demonstrated on imaging, especially computed tomography and MRI. Some of these lesions, especially those of steatosis and sinusoidal obstruction syndrome, are associated with a worse prognosis and risk of hepatic failure in the context of surgical management. Notably, some chemotherapy-induced hepatic alterations, such as sinusoidal obstruction syndrome, pseudocirrhosis and focal hepatopathies, may be mistakenly interpreted as signs of cancer progression, misguiding the therapeutic planning for patients receiving chemotherapy.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 4","pages":"HEP32"},"PeriodicalIF":5.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/ad/hep-08-32.PMC8577512.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39701719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信